Emphysema severity index (ESI) associated with respiratory death in a large Swedish general population.

Recently, it has been shown and validated that presence and severity of emphysema on computed tomography could be estimated by a novel spirometry based index, the emphysema severity index (ESI). However, the clinical relevance of the index has not been established. We conducted cox-regression analyses with adjustment for age, smoking, sex, forced expiratory volume in 1 s (FEV ₁ ) and forced vital capacity (FVC) to study whether ESI was associated with all-cause, respiratory and non-respiratory 10-year mortality. Study population was all participants with acceptable spirometry from the Gott Åldrande i Skåne study, a Swedish general population aged 65-102 years old. ESI is expressed as a continuous numeric parameter on a scale ranging from 0 to 10. Out of the 4453 participants in the main study, 3974 was included in the final analysis. Higher age, higher ESI, lower FEV ₁ and male sex increased hazard of respiratory death. ESI was significantly correlated to respiratory death but not non-respiratory death, while high age, male sex and low FEV ₁ was associated with non-respiratory as well as respiratory death. Current smoking habits increased the hazard of respiratory death but did not reach significance (p 0.066) One unit increase in ESI increased hazard of all-cause death by 20% (p 0.0002) and hazard of respiratory death by 57% (p < 0.0001). The ESI is a novel clinical marker of emphysema severity that is associated with respiratory death specifically. Since it can be derived from standard spirometry there are potential benefits for clinical practice in terms of more individualised prognosis and treatment alternatives.
Competing Interests: Declaration of competing interest Dr. Occhipinti reports grants from Fondazione Menarini, personal fees from Novartis, outside the submitted work; Dr. Wollmer reports grants from Swedish Heart and Lung Foundation, grants from Lund University, grants from Skåne Region, during the conduct of the study; personal fees from Chiesi Pharma, outside the submitted work; In addition, Dr. Wollmer has a patent Device and method for pulmonary function measurement issued.. Dr. Luoto reports grants from Skåne County, during the conduct of the study.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)